Kiromic BioPharma, Inc. Common Stock
KRBP
KRBP was delisted on the 13th of September, 2023.
20 hedge funds and large institutions have $3.82M invested in Kiromic BioPharma, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 7 closing their positions.
800% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 1
497% more call options, than puts
Call options by funds: $585K | Put options by funds: $98K
0.38% more ownership
Funds ownership: 15.8% → 16.18% (+0.38%)
13% less funds holding
Funds holding: 23 → 20 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
49% less capital invested
Capital invested by funds: $7.49M → $3.82M (-$3.67M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$334K |
| 2 |
LPL Financial
San Diego,
California
|
+$71.7K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$49.5K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$43.5K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$37.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1CM
1492 Capital Management
Milwaukee,
Wisconsin
|
-$1.33M |
| 2 |
IP
Intellectus Partners
San Francisco,
California
|
-$303K |
| 3 |
VF
Virtu Financial
New York
|
-$54K |
| 4 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
-$31K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$24.5K |
KRBP Hedge Fund Activity: Q4 2021 in Review
20 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Kiromic BioPharma, Inc. Common Stock (KRBP) for Q4 2021, worth a combined $3.82M — down 49% from $7.49M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of KRBP and 4 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 9 added.
The largest buyer was Sabby Management, adding an estimated $334K. The largest seller was 1492 Capital Management, exiting entirely with an estimated $1.33M sold.
- 20 institutional investors held Kiromic BioPharma, Inc. Common Stock (KRBP) as of Q4 2021, down from 23 in Q3 2021.
- Funds reported $3.82M of Kiromic BioPharma, Inc. Common Stock stock for Q4 2021, down 49% quarter-over-quarter.
- 4 funds opened new Kiromic BioPharma, Inc. Common Stock positions in Q4 2021 and 7 closed out, a net change of -3 holders.
- The largest Kiromic BioPharma, Inc. Common Stock buyer in Q4 2021 was Sabby Management, an estimated $334K added.
- The largest Kiromic BioPharma, Inc. Common Stock seller in Q4 2021 was 1492 Capital Management, an estimated $1.33M sold.
Based on aggregated 13F filings for Q4 2021.